Company intelligence / Profile preview

ARIAD Pharmaceuticals, Inc.

Cambridge, Massachusetts, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~380
Development stage: Commercial

Overview

ARIAD developed and commercialized Iclusig (ponatinib) for treatment of CML and Ph+ ALL. Brigatinib, an ALK inhibitor for NSCLC, completed its registration trial in 2016 and received FDA approval in April 2017.

Therapeutic areas: Oncology
Modalities: Small moleculesTyrosine kinase inhibitors (TKIs)
Industry: Biotech

Drug pipeline

1 asset

ponatinib

Commercial

Indications: Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Partnerships

Medinol Ltd. (for development and commercialization of stents and medical devices to deliver ridaforolimus)

Beyond the preview

Go deeper on ARIAD Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARIAD Pharmaceuticals, Inc..

Explore the full profile